Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: Design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study

Cardiovascular Ultrasound

Volumn 10, Issue 1, 2012, Pages

  Kretzschmar, Daniel ^a   Jung, Christian ^a   Otto, Sylvia ^a   Utschig, Stephan ^a   Hartmann, Michael ^a   Lehmann, Thomas ^a   Yilmaz, Atilla ^a   Pörner, Tudor C ^a   Figulla, Hans R ^a   Ferrari, Markus ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; HEPARIN; PLACEBO;

ARTERY EMBOLISM; ARTICLE; CONTROLLED STUDY; CORONAR EMBOL; CORONARY ARTERY; CORONARY FLOW RESERVE; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAM; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE PAYMENT; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861207298     PISSN: None     EISSN: 14767120     Source Type: Journal    
DOI: 10.1186/1476-7120-10-21     Document Type: Article

References (23)

1. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Herrmann J, Haude M, Lerman A, Schulz R, Volbracht L, Ge J, Schmermund A, Wienecke A, von Birgelen C, Eggebrecht H, Baumgart D, Heusch G, Erbel R, Circulation 2001 103 2339 2345 10.1161/01.CIR.103.19.2339 11352881 (Pubitemid 32448797)
2. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Johansen O, Brekke M, Stromme JH, Valen V, Seljeflot I, Skjaeggestad O, Arnesen H, Eur Heart J 1998 19 112 117 10.1053/euhj.1997.0732 9503183 (Pubitemid 28112307)
3. Coronary microembolization. Erbel R, Heusch G, J Am Coll Cardiol 2000 36 22 24 10.1016/S0735-1097(00)00708-7 10898407 (Pubitemid 30466106)
4. Troponin, embolization and restoration of micro-vascular integrity. Brener SJ, Topol EJ, Eur Heart J 2000 21 1117 1119 10.1053/euhj.2000.2119 10924291 (Pubitemid 30438633)
5. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR, Rihal CS, J Am Coll Cardiol 2006 48 1765 1770 10.1016/j.jacc.2006.04.102 17084247 (Pubitemid 44648624)
6. Peri-procedural myocardial injury: 2005 update. Herrmann J, Eur Heart J 2005 26 2493 2519 10.1093/eurheartj/ehi455 16176941 (Pubitemid 41679359)
7. Detection of coronary microembolization by doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Bahrmann P, Werner GS, Heusch G, Ferrari M, Poerner TC, Voss A, Figulla HR, Circulation 2007 115 600 608 10.1161/CIRCULATIONAHA.106.660779 17261655 (Pubitemid 46226170)
8. Coronary microembolization: from bedside to bench and back to bedside. Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schul R, Erbel R, Circulation 2009 120 1822 1836 10.1161/CIRCULATIONAHA.109.888784 19884481
9. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Jung C, Sörensson P, Saleh N, Arheden H, Ryden L, Pernow J, Atherosclerosis 2012 221 226 231 10.1016/j.atherosclerosis.2011.12.025 22245039
10. Detection of coronary microembolisation by Doppler ultrasound during percutaneous coronary interventions. Bahrmann P, Figulla HR, Wagner M, Ferrari M, Voss A, Werner GS, Heart 2005 91 1886 1192
11. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, Judd RM, Kim RJ, Circulation 2001 103 2780 2783 10.1161/hc2301.092121 11401931 (Pubitemid 32550063)
12. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury. Selvanayagam JB, Poro I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP, Circulation 2005 111 1027 1032 10.1161/01.CIR.0000156328.28485.AD 15723982 (Pubitemid 40354521)
13. High-sensitivity C-reactive protein: clinical importance. Bassuk SS, Rifai N, Ridker PM, Curr Probl Cardiol 2002 29 439 493
14. Inflammatory markers in coronary heart disease: coronary vascular versus myocardial origin? Heusch G, Schulz R, Erbel R, Pearson TA, Mensag GA, Alexander RW, Anderson JL, Cannon RO, Criqiu MH, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F, Circulation 2003 108 4 10.1161/01.CIR.0000079055.99427.3F 12847058
15. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG, Circulation 2001 104 992 997 10.1161/hc3401.095074 11524391 (Pubitemid 32803874)
16. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigators, N Engl J Med 1994 330 956 961 8121459
17. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patienst with acute myocardial infarction treated with primary coronary intervention. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP, Catheter Cardiovasc Interv 2004 62 186 192 10.1002/ccd.20041 15170708 (Pubitemid 38788695)
18. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators, N Engl J Med 1993 329 673 682 8204123
19. Meta-analysis of randomized trials comparing anti-embolic devices with standard PCI for improving myocardial reperfusion in patients with acute myocardial infarction. Kunadian B, Dunning J, Vijayalakshmi K, Thornley AR, de Belder MA, Catheter Cardiovasc Interv 2007 69 488 496 10.1002/ccd.20990 17286249 (Pubitemid 46363848)
20. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, LAllier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ, Circulation 2000 102 28 34 10.1161/01.CIR.102.1. 28 10880411 (Pubitemid 30430549)
21. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF, Coron Artery Dis 2008 19 271 277 10.1097/MCA. 0b013e3282f487e0 18480672
22. Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist. Junghans U, Siebler M, Circulation 2003 107 2717 2721 10.1161/01.CIR.0000070544.15890.0E 12742983 (Pubitemid 36667246)
23. Cerebral microembolism detected by transcranial Doppler during cardiac procedures. Stygall J, Kong R, Walker M, Hardman SMC, Harrison MJG, Newman SP, Stroke 2000 31 2508 2510 10.1161/01.STR.31.10.2508 11022086